Thr1989

Site Information
LCFPENEtPPEGkNM SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 2226546
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoassay ( 3 , 5 ) , immunoprecipitation ( 18 , 21 , 43 , 50 ) , mass spectrometry ( 14 , 17 , 19 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 32 , 34 , 35 , 36 , 37 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 ) , mutation of modification site ( 18 , 21 , 43 , 50 ) , phospho-antibody ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 13 , 15 , 16 , 18 , 20 , 21 , 31 , 43 ) , phosphoamino acid analysis ( 50 ) , western blotting ( 2 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 13 , 15 , 16 , 18 , 20 , 21 , 31 , 43 , 50 )
Disease tissue studied:	bone cancer ( 3 , 7 , 12 , 15 ) , breast cancer ( 18 , 19 ) , breast ductal carcinoma ( 19 ) , HER2 positive breast cancer ( 14 ) , luminal A breast cancer ( 14 ) , luminal B breast cancer ( 14 ) , breast cancer, triple negative ( 14 , 19 ) , colorectal cancer ( 18 , 21 , 43 , 50 ) , colorectal carcinoma ( 18 , 21 , 43 , 50 ) , gastric cancer ( 39 , 40 , 41 , 42 , 44 , 45 , 46 , 47 , 48 , 49 ) , gastric carcinoma ( 39 , 40 , 41 , 42 , 44 , 45 , 46 , 47 , 48 , 49 ) , leukemia ( 11 ) , chronic lymphocytic leukemia ( 11 ) , lung cancer ( 2 , 18 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 37 ) , non-small cell lung cancer ( 2 , 18 , 24 , 25 , 26 , 28 , 29 , 30 , 34 , 35 , 37 ) , non-small cell lung adenocarcinoma ( 18 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 35 ) , non-small cell large cell lung carcinoma ( 25 , 28 ) , non-small cell squamous cell lung carcinoma ( 27 ) , small-cell lung cancer ( 18 , 22 , 23 ) , pancreatic cancer ( 15 ) , pancreatic carcinoma ( 15 ) , cancer, squamous cell carcinoma ( 16 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 13 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 66 ) , A549 (pulmonary) ( 18 , 24 ) , bladder ( 8 ) , brain ( 5 ) , breast ( 14 , 19 ) , Cal-12T (pulmonary) ( 30 ) , Calu-3 (pulmonary) ( 26 ) , DMS153 (pulmonary) ( 29 ) , DMS53 (pulmonary) ( 23 ) , DMS79 (pulmonary) ( 22 ) , EHEB (B lymphocyte) ( 11 ) , epithelial ( 4 ) , HaCaT (keratinocyte) ( 12 ) , HCC15 (pulmonary) ( 27 ) , HCC366 (pulmonary) ( 37 ) , HCC44 (pulmonary) ( 30 ) , HCC78 (pulmonary) ( 28 , 37 ) , HCC827 (pulmonary) ( 26 ) , HCT116 (intestinal) ( 18 , 21 , 43 , 50 ) , HEK293T (epithelial) ( 20 , 21 , 43 ) , HeLa (cervical) ( 9 , 17 , 20 , 31 , 43 , 51 , 52 , 54 , 55 , 69 , 70 ) , HeLa S3 (cervical) ( 68 ) , HeLa_Meta (cervical) ( 63 ) , HeLa_Pro (cervical) ( 63 ) , HeLa_Telo (cervical) ( 63 ) , HT-29 (intestinal) ( 18 ) , Jurkat (T lymphocyte) ( 32 , 53 , 64 , 65 , 67 ) , K562 (erythroid) ( 36 ) , LOU-NH91 (squamous) ( 27 , 37 ) , lung ( 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ) , MCF-7 (breast cell) ( 18 ) , MKN-45 (gastric) ( 39 , 40 , 41 , 42 , 44 , 45 , 46 , 47 , 48 , 49 ) , NCI-H128 (pulmonary) ( 22 ) , NCI-H1299 (pulmonary) ( 25 ) , NCI-H1355 (pulmonary) ( 24 ) , NCI-H1395 (pulmonary) ( 2 ) , NCI-H1417 (pulmonary) ( 22 ) , NCI-H1437 (pulmonary) ( 29 , 30 ) , NCI-H146 (pulmonary) ( 18 ) , NCI-H1650 (pulmonary) ( 26 ) , NCI-H1666 (pulmonary) ( 30 ) , NCI-H1703 (squamous) ( 27 ) , NCI-H1734 (pulmonary) ( 25 ) , NCI-H1781 (pulmonary) ( 28 ) , NCI-H1792 (pulmonary) ( 24 ) , NCI-H1944 (pulmonary) ( 25 ) , NCI-H1975 (pulmonary) ( 26 ) , NCI-H2073 (pulmonary) ( 27 , 29 ) , NCI-H209 (pulmonary) ( 22 , 29 ) , NCI-H2106 (pulmonary) ( 26 ) , NCI-H2228 (pulmonary) ( 28 , 35 ) , NCI-H23 (pulmonary) ( 24 ) , NCI-H2342 (pulmonary) ( 27 ) , NCI-H2405 (pulmonary) ( 30 ) , NCI-H3122 (pulmonary) ( 28 , 34 ) , NCI-H358 (pulmonary) ( 25 ) , NCI-H441 (pulmonary) ( 24 ) , NCI-H446 (pulmonary) ( 23 ) , NCI-H460 (pulmonary) ( 25 , 37 ) , NCI-H524 (pulmonary) ( 22 ) , NCI-H526 (pulmonary) ( 23 ) , NCI-H661 (pulmonary) ( 28 ) , NCI-H69 (pulmonary) ( 23 ) , NCI-H82 (pulmonary) ( 23 ) , NCI-H838 (pulmonary) ( 29 ) , OKF4 (epithelial) ( 16 ) , PANC-1 (pancreatic) ( 15 ) , SNU-2670 ( 6 ) , U2OS (bone cell) ( 3 , 7 , 12 , 15 ) , UMSCC11B (squamous) ( 16 ) , UMSCC38 (squamous) ( 16 )

Upstream Regulation
Regulatory protein:	ATRIP (human) ( 50 ) , CASP2 (human) ( 7 ) , CDC5L (human) ( 20 ) , CtIP (human) ( 15 ) , HORMAD1 (human) ( 2 ) , PRPF19 (human) ( 20 ) , RPA1 (human) ( 50 ) , TOPBP1 (human) ( 43 , 50 ) , UHRF2 (human) ( 9 )
Putative in vivo kinases:	ATR (human) ( 12 , 43 )
Kinases, in vitro:	ATR (human) ( 50 )
Treatments:	AZ20 ( 43 ) , AZD6738 ( 8 ) , caffeine ( 43 , 50 ) , camptothecin ( 7 , 12 , 20 ) , CdA ( 11 ) , etoposide ( 7 , 16 ) , fludarabine ( 11 ) , HAMNO ( 16 ) , hydroxyurea ( 2 , 7 , 13 , 21 , 43 , 50 ) , ionizing_radiation ( 21 , 43 , 50 ) , KU-55933 ( 43 , 50 ) , MK1775 ( 15 ) , NA-AAF ( 12 ) , NU7026 ( 50 ) , NU7441 ( 43 ) , olaparib ( 6 ) , seliciclib ( 15 , 50 ) , thioridazine ( 13 ) , TMZ ( 8 ) , topotecan ( 7 ) , UCN-01 ( 50 ) , UV ( 9 , 43 , 50 ) , UVC ( 21 ) , VE-821 ( 3 , 8 , 12 ) , VE822 ( 8 )

Downstream Regulation
Effects of modification on ATR:	enzymatic activity, induced ( 9 , 12 , 43 , 50 ) , molecular association, regulation ( 50 ) , phosphorylation ( 9 )
Effects of modification on biological processes:	apoptosis, inhibited ( 8 ) , carcinogenesis, induced ( 6 , 8 ) , cell cycle regulation ( 8 , 18 ) , cell growth, induced ( 6 ) , chromatin organization, altered ( 9 )
Induce interaction with:	TOPBP1 (human) ( 50 )

References
1	Arends T, Tsuchida H, Adeyemi RO, Tapscott SJ (2024) DUX4-induced HSATII transcription causes KDM2A/B-PRC1 nuclear foci and impairs DNA damage response. J Cell Biol 223 38451221 Curated Info
2	Herrera LR, et al. (2023) The cancer testes antigen, HORMAD1, limits genomic instability in cancer cells by protecting stalled replication forks. J Biol Chem 299, 105348 37838177 Curated Info
3	Joo YK, et al. (2023) ATR promotes clearance of damaged DNA and damaged cells by rupturing micronuclei. Mol Cell 83, 3642-3658.e4 37788673 Curated Info
4	Igarashi T, et al. (2023) An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress. Nat Commun 14, 4991 37591859 Curated Info
5	Nelson TJ, Xu Y (2023) Sting and p53 DNA repair pathways are compromised in Alzheimer's disease. Sci Rep 13, 8304 37221295 Curated Info
6	Oh KS, et al. (2022) A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oncogene 35798878 Curated Info
7	Boice AG, et al. (2021) Caspase-2 regulates S-phase cell cycle events to protect from DNA damage accumulation independent of apoptosis. Oncogene 34718349 Curated Info
8	El Touny LH, et al. (2021) ATR inhibition reverses the resistance of homologous recombination deficient MGMT/MMR cancer cells to temozolomide. Oncotarget 12, 2114-2130 34676045 Curated Info
9	Hanaki S, Habara M, Shimada M (2021) UV-induced activation of ATR is mediated by UHRF2. Genes Cells 33848395 Curated Info
10	Ito SS, et al. (2020) Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways. J Biol Chem 32675286 Curated Info
11	Beyaert M, et al. (2017) Reevaluation of ATR signaling in primary resting chronic lymphocytic leukemia cells: evidence for pro-survival or pro-apoptotic function. Oncotarget 8, 56906-56920 28915641 Curated Info
12	Kemp MG (2017) DNA damage-induced ATM- and Rad-3-related (ATR) kinase activation in non-replicating cells is regulated by the XPB subunit of transcription factor IIH (TFIIH). J Biol Chem 292, 12424-12435 28592488 Curated Info
13	Singh V, Connelly ZM, Shen X, De Benedetti A (2017) Identification of the proteome complement of humanTLK1 reveals it binds and phosphorylates NEK1 regulating its activity. Cell Cycle 16, 915-926 28426283 Curated Info
14	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
15	Saini P, Li Y, Dobbelstein M (2015) Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress. Oncotarget 6, 13072-87 25965828 Curated Info
16	Glanzer JG, et al. (2014) RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res 74, 5165-72 25070753 Curated Info
17	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
18	Hirokawa T, et al. (2014) CBP-93872 inhibits NBS1-mediated ATR activation, abrogating maintenance of the DNA double-strand break-specific G2 checkpoint. Cancer Res 74, 3880-9 24876101 Curated Info
19	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
20	Maréchal A, et al. (2014) PRP19 Transforms into a Sensor of RPA-ssDNA after DNA Damage and Drives ATR Activation via a Ubiquitin-Mediated Circuitry. Mol Cell 53, 235-46 24332808 Curated Info
21	Luzwick JW, Nam EA, Zhao R, Cortez D (2014) Mutation of Serine 1333 in the ATR HEAT Repeats Creates a Hyperactive Kinase. PLoS One 9, e99397 24901225 Curated Info
22	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
23	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
24	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
25	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
26	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
27	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
28	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
29	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
30	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
31	Vidal-Eychenié S, Décaillet C, Basbous J, Constantinou A (2013) DNA structure-specific priming of ATR activation by DNA-PKcs. J Cell Biol 202, 421-9 23897887 Curated Info
32	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
33	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
34	Rikova K (2013) CST Curation Set: 18860; Year: 2012; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT Curated Info
35	Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT Curated Info
36	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
37	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
38	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
39	Mulhern D (2011) CST Curation Set: 12647; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: TPP Motif (TPP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) TPP Motif (TPP) Immunoaffinity Beads Cat#: 5758 Curated Info
40	Mulhern D (2011) CST Curation Set: 12863; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: TPP Motif (TPP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) TPP Motif (TPP) Immunoaffinity Beads Cat#: 5758 Curated Info
41	Mulhern D (2011) CST Curation Set: 12864; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: TPP Motif (TPP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) TPP Motif (TPP) Immunoaffinity Beads Cat#: 5758 Curated Info
42	Mulhern D (2011) CST Curation Set: 12865; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: TPP Motif (TPP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) TPP Motif (TPP) Immunoaffinity Beads Cat#: 5758 Curated Info
43	Nam EA, et al. (2011) Thr-1989 Phosphorylation Is a Marker of Active Ataxia Telangiectasia-mutated and Rad3-related (ATR) Kinase. J Biol Chem 286, 28707-14 21705319 Curated Info
44	Moritz A (2011) CST Curation Set: 12381; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
45	Moritz A (2011) CST Curation Set: 12382; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
46	Moritz A (2011) CST Curation Set: 12383; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
47	Moritz A (2011) CST Curation Set: 12384; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
48	Moritz A (2011) CST Curation Set: 12385; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
49	Moritz A (2011) CST Curation Set: 12386; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
50	Liu S, et al. (2011) ATR Autophosphorylation as a Molecular Switch for Checkpoint Activation. Mol Cell 43, 192-202 21777809 Curated Info
51	Zhou J (2010) CST Curation Set: 10710; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
52	Zhou J (2010) CST Curation Set: 10711; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
53	Possemato A (2010) CST Curation Set: 10723; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
54	Zhou J (2010) CST Curation Set: 10689; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
55	Zhou J (2010) CST Curation Set: 10686; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
56	Guo A (2010) CST Curation Set: 9972; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
57	Guo A (2010) CST Curation Set: 9968; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
58	Guo A (2010) CST Curation Set: 9975; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
59	Guo A (2010) CST Curation Set: 9969; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
60	Guo A (2010) CST Curation Set: 9973; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
61	Guo A (2010) CST Curation Set: 9971; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
62	Guo A (2010) CST Curation Set: 9974; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
63	Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81 20097925 Curated Info
64	Possemato A (2010) CST Curation Set: 9440; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
65	Possemato A (2010) CST Curation Set: 9439; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: TPP Motif (TPP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) TPP Motif (TPP) Immunoaffinity Beads Cat#: 5758 Curated Info
66	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
67	Possemato A (2009) CST Curation Set: 6850; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
68	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info
69	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
70	Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5 15302935 Curated Info